STEN Stock Chart & Stats
$4038.00
-$0.57(-0.01%)
At close: 4:00 PM EDT
$4038.00
-$0.57(-0.01%)
Day’s Range― - ―
52-Week Range$3,768.31 - $4,271.69
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$416.29B
Enterprise Value$22.19B
Total Cash (Recent Filing)$482.30M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)27.9
Beta-0.02
Next Earnings
Nov 05, 2026EPS Estimate
50.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.20
Shares Outstanding97,500,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,063.80Price Target Upside25.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)209.93
Revenue Forecast (FY)$119.37B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelSTERIS combines capital equipment with recurring consumables, service contracts, lifecycle support, and outsourced sterilization. This installed-base model can deepen customer relationships, support predictable demand, and make revenue more resilient than a business dependent only on periodic equipment sales.
Healthcare Growth And Margin ExpansionRecent growth was accompanied by meaningful gross- and EBIT-margin expansion, indicating that pricing, productivity, mix, and cost discipline are translating into operating leverage. That combination strengthens earnings quality and supports continued investment across STERIS’s healthcare and life-sciences franchises.
Conservative Balance SheetVery low reported leverage gives STERIS substantial financial flexibility to fund operations, invest in capacity, and manage industry volatility. Improved returns on equity also suggest that the company is generating stronger earnings from its capital base, reinforcing balance-sheet quality over the medium term.
Bears Say
Debt-Financed Xodus AcquisitionThe Xodus transaction represents a major capital deployment and is expected to increase leverage from STERIS’s currently conservative position. Integration, financing, and execution requirements could reduce financial flexibility before the acquired specialty surgical portfolio produces its expected strategic benefits.
Heavy Multi-Year Investment And RestructuringThe chemistry consolidation requires substantial capital spending across fiscal 2027-2029 while also creating sizable restructuring costs. These commitments can suppress free cash flow and raise execution demands in the medium term, even if the new capacity ultimately improves efficiency and supports growth.
Life Sciences Margin PressureMargin compression in Life Sciences indicates that pricing and volume gains are not currently fully offsetting productivity challenges and inflation. If these pressures persist, they could dilute consolidated profitability and limit the earnings benefit from continued revenue growth in an important operating segment.
Steris News
STEN FAQ
What was Steris plc’s price range in the past 12 months?
Steris plc lowest stock price was $3768.31 and its highest was $4271.69 in the past 12 months.
What is Steris plc’s market cap?
Steris plc’s market cap is $416.29B.
When is Steris plc’s upcoming earnings report date?
Steris plc’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.
How were Steris plc’s earnings last quarter?
Steris plc released its earnings results on Aug 05, 2026. The company reported $48.336 earnings per share for the quarter, beating the consensus estimate of $46.563 by $1.773.
Is Steris plc overvalued?
According to Wall Street analysts Steris plc’s price is currently Undervalued.
Does Steris plc pay dividends?
Steris plc does not currently pay dividends.
What is Steris plc’s EPS estimate?
Steris plc’s EPS estimate is 50.03.
How many shares outstanding does Steris plc have?
Steris plc has 97,500,110 shares outstanding.
What happened to Steris plc’s price movement after its last earnings report?
Steris plc reported an EPS of $48.336 in its last earnings report, beating expectations of $46.563. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Steris plc?
Currently, no hedge funds are holding shares in MX:STEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,063.80 (25.40% Upside)
$5,063.80 (25.40% Upside)
Blogger Sentiment
Bullish
MX:STEN Sentiment 63%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $17.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.09%
12-Months-Change
Fundamentals
Return on Equity
11.27%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Steris plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
STEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive. STERIS delivered solid revenue, margin, and EPS growth; maintained its fiscal 2027 outlook; reported strong Healthcare and Life Sciences demand; and announced a major long-term chemistry capacity investment. These strengths were partially offset by lower free cash flow, a higher tax rate, AST inventory destocking and margin pressure, Life Sciences margin compression, restructuring charges, and substantial planned capital spending.View all MX:STEN earnings summariesSTEN Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
STEN Stock 12 Month Forecast
Average Price Target
$5,063.80
▲(25.40% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Mesa Laboratories
―
QuidelOrtho
―
Trinity Biotech
―